How Strong Is Norco Compared to Other Opioids?

Norco, a brand-name combination of hydrocodone and acetaminophen, sits in the middle tier of opioid strength. Milligram for milligram, hydrocodone (the opioid ingredient in Norco) is roughly equivalent to oral morphine and slightly weaker than oxycodone, while being substantially stronger than codeine or tramadol and far weaker than drugs like fentanyl or hydromorphone. Where things get interesting is in the details: how “strength” is measured, what the acetaminophen component adds and limits, and why potency rankings from clinical pain studies don’t always match what receptor-binding data or abuse-liability research would predict.

How Hydrocodone Compares to Morphine

The most common way clinicians compare opioids is through morphine milligram equivalents, which use oral morphine as the reference point. By that standard, hydrocodone and oral morphine are close to interchangeable: roughly 30 mg of oral morphine provides the same level of pain relief as 30 mg of oral hydrocodone.¹ That 1-to-1 ratio is the starting estimate used in emergency departments and pain clinics when switching a patient from one drug to the other.

In practice, though, this ratio isn’t as clean as it sounds. A study of cancer patients being rotated from hydrocodone to other strong opioids found the real-world conversion ratio varied depending on how much hydrocodone someone was already taking. For patients on less than 40 mg of hydrocodone per day, the median conversion to morphine equivalents was about 2-to-1, meaning doctors needed roughly twice as much morphine-equivalent dosing to replace their hydrocodone. For patients on 40 mg or more per day, the ratio dropped to about 1.1-to-1, much closer to the textbook figure.² The takeaway is that standard conversion charts are rough guides, not exact formulas, and individual variation matters a lot.

Norco Versus Oxycodone (Percocet)

Oxycodone, the opioid in Percocet and OxyContin, is the drug people most commonly compare to hydrocodone. At the receptor level, oxycodone binds more strongly to the mu-opioid receptor than hydrocodone does.³ In human abuse-liability studies, the potency ranking consistently comes out as oxycodone being roughly equal to or slightly more potent than hydrocodone.⁴

Yet when researchers actually tested the two head-to-head for fracture pain in a double-blind trial, the difference in pain relief was not statistically significant. At 30 minutes, oxycodone patients reported a mean pain reduction of 3.7 points and hydrocodone patients 2.5 points, but the confidence intervals overlapped and the between-group difference was not meaningful. At 60 minutes, the gap was similarly small and statistically insignificant.⁵ So while oxycodone has a modest edge in lab-measured potency, in a real clinical scenario with standard doses, most patients won’t notice a dramatic difference between the two.

How Norco Stacks Up Against Weaker Opioids

Compared to codeine, hydrocodone is a clear step up. In a trial of acute musculoskeletal pain, patients on hydrocodone had fewer treatment failures than those on codeine, and hydrocodone caused fewer central nervous system side effects like drowsiness and dizziness.⁶ This matches the receptor-binding data, which places hydrocodone well above codeine in mu-opioid affinity.

Tramadol is another drug that frequently comes up. In a post-oral-surgery trial, two tablets of tramadol/acetaminophen (75/650 mg per tablet) provided comparable pain relief to one tablet of hydrocodone/acetaminophen, though hydrocodone kicked in a bit faster, with a median onset around 25 minutes versus 34 minutes for the tramadol combination. The duration of relief, measured by how long before patients asked for more pain medication, was not significantly different between the two groups.⁷ The fact that it took twice the tramadol dose to match hydrocodone underscores that tramadol is the weaker drug on a milligram-per-milligram basis.

Where Norco Sits Below the Strong Opioids

When you move up the potency ladder, the gap between Norco and the stronger opioids widens fast. Receptor-binding studies rank common opioids in this approximate order from strongest to weakest binding at the mu-opioid receptor: buprenorphine, hydromorphone, oxymorphone, morphine, oxycodone, hydrocodone, tapentadol, and tramadol.³ Hydromorphone (Dilaudid), for example, is commonly estimated at four to eight times more potent than oral morphine, placing it well above hydrocodone. Fentanyl is in another league entirely, roughly 50 to 100 times more potent than morphine.

These potency differences matter most for understanding overdose risk and why switching between opioids requires careful dose calculation. They don’t mean that Norco is an ineffective painkiller for the conditions it’s prescribed for. It means the drug has a defined ceiling of strength, and patients whose pain has outgrown Norco-level doses usually need to move to a different medication rather than just take more tablets, especially given the acetaminophen component.

The Acetaminophen Factor

Norco isn’t just hydrocodone. It pairs the opioid with 325 mg of acetaminophen per tablet, and that combination does real work. In factorial-design studies, combining hydrocodone with a non-opioid analgesic like ibuprofen produced pain relief that was significantly greater than either drug alone, consistent with an additive effect where each component contributes independently.⁸ The same principle applies to the hydrocodone-acetaminophen pairing in Norco. You get meaningful pain relief from the acetaminophen portion, which allows the hydrocodone dose to stay lower.

But acetaminophen also imposes a hard safety ceiling. Taking too many Norco tablets means ingesting dangerous amounts of acetaminophen, which can cause severe liver damage. A review of prescription acetaminophen poisoning cases found that tablets with 500 mg or more of acetaminophen were involved in 80% of cases resulting in liver injury or death, and the FDA subsequently asked manufacturers to cap acetaminophen in combination products at 325 mg per tablet.⁹ The combination with over-the-counter acetaminophen products (like Tylenol) is especially dangerous, because patients may not realize they’re doubling up on the same drug.

In a study of substance abusers, the acetaminophen in hydrocodone products actually served as a deterrent against dose escalation. Oxycodone was preferred as a primary drug of abuse by a larger share of users (about 45%) than hydrocodone (about 29%), partly because oxycodone was perceived as producing a better high, but also because hydrocodone users cited the acetaminophen as a reason they couldn’t easily increase their dose to chase euphoria.¹⁰ So the combination formula functions as a kind of built-in brake, though it obviously doesn’t prevent misuse entirely.

Hydrocodone and Ibuprofen Combinations

Norco isn’t the only hydrocodone combination on the market. Vicoprofen pairs hydrocodone with ibuprofen instead of acetaminophen. In a chronic-pain trial comparing hydrocodone/ibuprofen at two dose levels against codeine/acetaminophen, the higher-dose hydrocodone/ibuprofen group showed significantly better daily pain relief scores, needed fewer daily doses, and required less supplemental pain medication. Only about 1% of patients in that group dropped out due to inadequate pain control, versus about 8% of the codeine/acetaminophen group.¹¹ For someone who needs hydrocodone but worries about acetaminophen-related liver risk, especially if they take other acetaminophen-containing products, the ibuprofen combination can be a practical alternative, though ibuprofen carries its own risks for the stomach and kidneys.

Respiratory Depression and Overdose Risk

Opioid overdose deaths happen primarily through respiratory depression, where the drug slows breathing to a dangerous degree. Among common prescription opioids, the risk varies dramatically by drug. A study of opioid overdose cases found that fentanyl was associated with severe respiratory depression in over 83% of cases, while codeine was associated with it in fewer than 4%.¹² Hydrocodone and oxycodone fell in between, classified as moderate-risk drugs in a large study that identified fentanyl, morphine, and methadone as the strongest predictors of serious opioid-induced respiratory depression, with hydrocodone, oxycodone, hydromorphone, and oxymorphone in a second tier of moderate association.¹³

This middle-tier placement makes intuitive sense given hydrocodone’s potency ranking. It’s strong enough to suppress breathing when taken in excess or combined with other sedating substances like benzodiazepines or alcohol, but it doesn’t carry the extreme per-milligram risk of fentanyl or methadone. That said, “moderate risk” is not “low risk,” and a large share of opioid overdose deaths in the United States have historically involved hydrocodone products simply because they were so widely prescribed.

Abuse Liability Compared to Other Opioids

How addictive a drug feels to someone misusing it doesn’t always track neatly with clinical potency. In laboratory studies giving intravenous opioids to experienced recreational users, oxycodone, morphine, and hydrocodone all produced the expected mu-agonist profile of pupil constriction, euphoria, and increased “liking” ratings. But the potency ranking for subjective effects came out as oxycodone slightly ahead of morphine, with hydrocodone last of the three.¹⁴

Interestingly, hydromorphone, which is estimated to be several times more potent than hydrocodone as an analgesic, turned out to be less than two-fold more potent in abuse-liability testing. That gap between analgesic potency charts and real-world abuse potential led researchers to conclude that standard pain-relief equivalence tables may not accurately predict how much people will misuse a given opioid.⁴

Formulation also affects abuse potential. Extended-release versions of hydrocodone, designed to deter tampering, produced lower and delayed peak “drug liking” scores compared with equal doses of immediate-release hydrocodone in recreational opioid users. Even crushing the extended-release tablets didn’t fully eliminate the delay in peak effects.¹⁵

What Happened When Hydrocodone Was Rescheduled

Until 2014, hydrocodone combination products like Norco were classified as Schedule III controlled substances in the United States, meaning they faced fewer prescribing restrictions than Schedule II drugs like oxycodone and morphine. The reclassification to Schedule II, which required written prescriptions (no phone-ins), limited refills, and imposed stricter dispensing rules, had a dramatic effect on prescribing patterns. In Ohio alone, hydrocodone prescriptions dropped by about 6% immediately and continued declining by roughly an additional 1% per month afterward.¹⁶

The drop wasn’t purely a win, though. Some prescribers switched patients to other drugs. Codeine prescriptions temporarily jumped by about 19% in Ohio, and a broader systematic review across multiple studies found increases in prescribing of oxycodone (up 5-14%), tramadol (up 3-53%), and codeine products (up anywhere from 1% to a startling 1,353% in some settings).¹⁷ Some of these substitutions traded a moderate opioid for a weaker but less-regulated one, while others shifted patients to oxycodone, which is arguably the same or slightly stronger. After surgical procedures, the initial prescriptions written after the schedule change actually contained about 35 more morphine equivalents on average, equivalent to roughly seven extra 5 mg hydrocodone tablets, though refill rates dropped significantly.¹⁸

Special Populations and Dose Adjustments

Norco’s effective strength changes depending on who is taking it. In people with kidney or liver problems, the body clears hydrocodone more slowly, so the same tablet produces higher drug levels in the blood. Pharmacokinetic studies of extended-release hydrocodone found that people with moderate kidney impairment had systemic exposure up to about 70% higher than people with normal kidney function. Moderate liver impairment also roughly doubled the drug’s total exposure in the body.¹⁹ For these patients, what looks like a moderate dose on paper can behave like a strong one.

Older adults face a similar dynamic. Age-related declines in liver and kidney function slow drug metabolism, and older people generally have less physical reserve to tolerate side effects like sedation and respiratory depression. Opioids remain a mainstay of pain treatment in older adults, but the margin for error is thinner, and clinicians typically start at lower doses and increase cautiously.²⁰

Hydrocodone Use During Pregnancy

The choice of opioid during pregnancy has consequences that extend beyond pain relief. A large study examining neonatal opioid withdrawal syndrome (NOWS) used hydrocodone as the reference point and found that codeine carried a lower risk, while stronger opioids carried substantially higher risk. Compared with hydrocodone, oxycodone was associated with about twice the risk of NOWS, morphine with about three times the risk, and methadone with roughly three times the risk as well. Tramadol’s risk was statistically similar to hydrocodone’s. Codeine came in at about 43% lower risk.²¹ These relative risks roughly mirror the potency hierarchy, though the relationship isn’t perfectly linear, and other factors like duration of use and trimester of exposure also play a role.

This data doesn’t mean hydrocodone is “safe” during pregnancy. All opioid use in pregnancy carries risks to the newborn. But it does illustrate that the choice between opioids is not purely about how well they control the mother’s pain; the downstream effects on the baby differ in ways that align loosely with where each drug sits on the potency scale.